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The long terminal repeats of maedi visna virus strain 1514 contain a consensus AP-1 binding site which has been shown
to be important in controlling virus transcription. However, this consensus site is absent in strain EV-1. Here, we have
compared the ability of oligonucleotides corresponding to LTR sequences from EV-1 with those from 1514 to bind transcrip-
tion factors in competitive gel retardation assays and activate reporter gene expression. The experiments demonstrated
no observable binding of AP-1 to the EV-1-derived sequences and significant differences in the abilities of the 1514 and
EV-1 sequences to activate transcription. However, both viral sequences interacted with a second, previously undetected,
transcription factor. This factor gave specific gel shifts which were competed by an oligonucleotide containing the consensus
sequence for the AML/PEBP2/CBF family of transcriptional factors, but not by control AP-1 or OCT-1 oligonucleotides. The
factor was therefore denoted AML (vis). A second AML (vis) site, noted upstream of the TATA box proximal AP-1 site, gave
single shifts which were competed by the downstream AML (vis) oligonucleotide. Both sites were functional in transfection
assays. In gel shift retardation assays, polyclonal antisera directed against known runt domain proteins were able to
supershift part of the AML (vis) binding activity in nuclear extracts from physiologically relevant cell types. The results thus
suggest that the AML (vis) binding factor belongs to the AML/PEBP2/CBF family of transcription factors and may be
important in controlling virus replication in these and other strains of ruminant lentiviruses. q 1997 Academic Press
Maedi-visna virus (MVV), an ovine lentivirus, causes a The 1514 LTR carries a consensus AP-1 site (Faisst and
Meyer, 1992), which has been demonstrated to bind theprogressive inflammatory and degenerative disease after
a prolonged incubation period (Sigurdsson et al., 1957; Si- AP-1 complex (Shih et al., 1992). A number of agents
known to trigger AP-1 activity by posttranscriptional mod-gurdsson and Palsson, 1958). Inflammatory responses are
observed in the lungs, joints, central nervous system (CNS), ification and to induce transcription of jun, fos, and fra
genes are also potent inducers of monocyte differentia-and other tissues (Hasse, 1986). The primary targets of
infection in vivo are cells of the monocyte/macrophage lin- tion and macrophage activation (Matsui et al., 1990; Lord
et al., 1990, 1993; Liebermann and Hoffman, 1994). Thiseage (Gendelman et al., 1985, 1986). Expression of the viral
genome within these cells appears to be controlled by both consensus AP-1 site is believed to be important not only
for basal transcription of the 1514 LTR, but also for tran-degree of differentiation and activation (Narayan et al., 1983;
scriptional activation mediated by the transactivating pro-Gendelman et al., 1986; Small et al., 1989). This restriction
tein tat (Gdovin and Clements, 1992; Hess et al., 1989;can be observed in vivo, where transcription of the MVV
Neuveut et al., 1993).genome appears to be limited to tissue resident macro-
In addition to 1514 (Sonigo et al., 1985), an Icelandicphages within the lungs, joints, and CNS (Gendelman et
isolate that is associated with the development of CNSal., 1986; Brodie et al., 1995). The transcription of the ge-
disease, there are a number of other geographically dis-nome occurs only in terminally differentiated macrophages,
tinct MVV isolates (Querat et al., 1990; Sargan et al.,as monocytes do not accumulate significant quantities of
1991). The EV-1 British strain was isolated from a sheepviral transcripts or proteins. The cellular and viral factors
with the pneumonic form of the disease. The EV-1 LTRthat govern this restricted stage of the viral lifecycle are
contains a number of base changes when compared toonly poorly understood.
the 1514 LTR. Sequence divergence between the 1514Using the long terminal repeat (LTR) from the MVV
and EV-1 viruses and sequence variation within the EV-strain 1514 as a model system, the cellular transcription
1 population leads to LTRs with distinct transcriptionalfactor AP-1 has been proposed as a key regulator of MVV
activities (Sargan et al., 1995). In both EV-1 and SA-OMVVtranscription (Gabuzda et al., 1989; Hess et al., 1989).
(a South African MVV isolate) there is no consensus AP-
1 site within the LTR. None of 54 EV-1 LTR sequences1 Present address: Department of Immunology, Box 180, M. D. Ander-
obtained directly from infected animals contained a con-son Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.
sensus AP-1 site (Sargan et al., 1995). In the present2 To whom correspondence and reprint requests should be ad-
dressed. report, the effect of this sequence divergence on tran-
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scriptional factor binding to the 1514 and EV-1 viruses at 377 for 1 hr or longer, and then the reaction was
stopped by adding 150 ml NaCO3 . The results were ex-was examined using oligonucleotides corresponding to
various regions of the LTR in gel retardation assays. pressed as optical density at 405 nm.
CAT assays were performed as described by SeedBinding of transcription factors to these sequences was
compared using gel retardation assays and by insertion and Sheen (1988). Briefly, 10 ml of cell extract was mixed
with 5 ml n-butyryl CoA (5 mg/ml), 2 ml [14C]-of oligonucleotides upstream of a basal promoter linked
to a bacterial chloramphenicol acetyl transferase (CAT) chloramphenicol (0.025 mCi/ml), and 113 ml 250 mM
Tris–HCl, pH 8.0. After being incubated for 3 hr at 377reporter gene.
the reactions were placed on ice and extracted with 250
ml of mixed xylenes (Aldrich Chemical Co., Dorset, UK).MATERIAL AND METHODS
After mixing, the tubes were spun at 13,500 rpm for 3
Cell lines and transfections
min. The upper organic phase was removed and ex-
tracted with 250 ml water. After this back-extraction, 125Ovine chondrocytes were isolated from cartilage discs
by digestion with collagenase (1 mg/ml) (Sigma Chemical ml of the organic phase was mixed with scintillation fluid
and counted for radioactivity.Co., Poole, Dorset) and cultured in DMEM supplemented
with 10% FCS for 5 passes. All transfection experiments
were performed using pass 5 frozen cell stocks. Ovine
Preparation of nuclear extracts
alveolar macrophages were obtained by bronchiolar la-
vage. Lungs were removed from animals at postmortem Nuclear extracts were prepared as described by
and washed extensively with light palpation with pre- Schreiber et al. (1989). Briefly, 1 1 107 cells were resus-
cooled (47) Hank’s balanced salt solution (HBSS). Recov- pended in 400 ml ice-cold hypotonic buffer A (10 mM
ered fluid was centrifuged for 15 min at 1500 g and the HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA,
resulting cell pellets were resuspended and pelleted 1 mM dithiothreitol). After 15 min of incubation, the cells
twice more through HBSS. When checked by cytospin were lysed by the addition of 25 ml of 10% Triton X-100.
these pellets contained approximately 90% macro- The sample was vortexed for 10 sec and the nuclei were
phages. Cells (3 1 108) were resuspended in 50 ml 0.32 immediately spun out and resuspended in 50 ml of 20
M sucrose containing 25 mM KCl, 3 mM MgCl2 , 0.1 mM mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM
DTT. Splenic extracts were obtained by first mincing 5 g EGTA, 1 mM DTT (buffer B). The nuclei were rocked
of spleen tissue into the same buffer. To recover nuclei, vigorously at 47 for 15 min, spun out, and then stored at
alveolar macrophages or splenic tissue was homoge- 0707. Prior to freezing, the protein concentration was
nized using 20 passes of a Potter type Teflon-glass ho- determined using a protein assay kit obtained from Bio-
mogenizer with a mechanical pestel. After larger debris Rad Laboratories Ltd. (Hemel Hempstead, Herts, UK),
was removed by filtering through a double layer of and the extract was diluted to 5 mg/ml in buffer B. All
cheesecloth, nuclei were pelleted by centrifugation (1500 buffers contained the following protease inhibitors: 5 mg/
g, 47, 15 min), and the supernatant was discarded. The ml aprotonin and leupeptin, 2 mg/ml pepstatin and 1 mM
crude nuclear pellet was resuspended in extraction phenylmethylsulphonyl fluoride (Sigma).
buffer and extracts were prepared as before.
Transfections were performed in 60-mm plastic dishes
Oligonucleotides and CAT vectors(3 1 106 cells) using calcium phosphate precipitation
(5 mg plasmid/plate) as described previously (Sargan et
Oligonucleotides, purified by high-pressure liquidal., 1995). Whole cell extracts were prepared from trans-
chromatography, were supplied by OSWELL DNA Ser-fected cells by freeze–thawing. The cells were scraped
vices, University of Edinburgh. The oligonucleotides cor-from plates after washing in phosphate-buffered saline
responding to the EV-1 and 1514 LTRs are shown incontaining 1 mM ethylene diamine tetraacetic acid
Fig. 1 and Table 1. The sequence denoted ‘‘EV-1’’ was(EDTA), microcentrifuged, and then resuspended in 250
obtained from strain EV-1 cultured in vitro in choroidmM Tris–HCl, pH 8.0. Lysis was performed with three
plexus cells, while ‘‘EV-1 (7)’’ was obtained from proviralcycles of transferring from dry ice/methanol to a 377 wa-
DNA recovered from cells in efferent lymph collectedter bath. Debris was removed by spinning at 13,500 rpm
from an MVV-infected sheep, i.e., ex vivo (Sargan et al.,for 5 min.
1995). Specific AP-1 (denoted AP-1 (control)) and OCT-1Transfection efficiency was controlled using a vector
oligonucleotides were generated using sequences fromthat expressed b-galactosidase (pSVbgal; Promega, En-
the human collagenase promoter (Lee et al., 1987) andterprise Road, Southampton, UK). b-Galactosidase was
the immunoglobulin k gene promoter (Parslow et al.,measured by mixing 50 ml of cell extract with 50 ml of
1984), respectively. The AP-1 oligonucleotide sequence21 b-galactosidase assay buffer (120 mM Na2HPO4 , 80
was chosen because it is a well-characterized AP-1 site.mM NaH2PO4 , 2 mM MgCl2 , 100 mM b-mercaptoethanol,
All nucleotides possessed SalI overhangs for cloning into1.33 mg/ml o-nitrophenyl-b-D-galactopyranoside) in a
flat-bottomed microtiter plate. The plate was incubated plasmids.
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Reporter constructs between the sequences affect putative transcription factor
sites. In both SA-OMVV and EV-1, base changes have mu-
For transfection analysis, double-stranded oligonucle- tated the consensus AP-1 site present in the 1514 virus
otides were cloned into the D56 vector comprising the (position 88). Although the 1514 virus contains a number
basal c-fos promoter upstream of a CAT gene (Gilman of degenerate AP-1 sites, only this TATA box proximal con-
et al., 1986), kindly supplied by Dr. J. Quinn, Medical sensus site has been shown to bind AP-1 in vitro (Gabuzda
Research Council, Brain Metabolism Unit, Edinburgh. et al., 1989; Shih et al., 1992). In the 1772 virus, a derivative
The oligonucleotides were inserted upstream of the of 1514 (Andresson et al., 1993), a consensus AP-1 site is
basal c-fos promoter using a SalI site. Plasmids con- still present, though its position is altered (Fig. 1) due to a
taining inserts were sequenced in order to determine the point mutation (position 66) in one of the degenerate AP-1
number and orientation of inserted sequences. sites present within the LTR. The EV-1 LTR contains the
same G-to-A transition within the TATA box proximal AP-1
Gel retardation assays site, but unlike the 1772 LTR there is no second site muta-
tion elsewhere in the LTR to regenerate a consensus siteFor gel retardations, oligonucleotides were labeled
(Fig. 1). Indeed, from previous sequencing studies, the up-with [g-32P]ATP using T4 polynucleotide kinase. Nuclear
stream AP-1 sites in the ex vivo EV-1 LTRs, e.g., EV-1(7),extract (5 mg) was preincubated for 5 min with sonicated
are further from consensus than those in 1514, with theand annealed poly(dI–dC)–poly(dI–dC) (5 mg; Sigma) as
exception of the potential site at position 24. The G-to-Aa nonspecific competitor prior to the addition of the radio-
transition in the TATA box proximal AP-1 site is found inlabeled probe in 51 retardation buffer (20% glycerol, 50
all sequenced EV-1 LTRs (Sargan et al., 1995) regardlessmM HEPES, pH 7.6, 5 mM MgCl2 , 2.5 mM EDTA, 2.5 mM
of whether they are obtained from virus passaged in vitroDTT). Competitor oligonucleotides were added to give a
or directly from infected animals (ex vivo). Studies on LTR500- or a 1000-fold molar excess and the mixture was
variants suggested the binding of a transcriptional activatorincubated for 5 min. Thereafter, 1 ml of radiolabeled probe
to this region because its duplication led to a twofold eleva-DNA was added and mixed, and the samples were incu-
tion in LTR activity (Sargan et al., 1995).bated for a further 10 min. All incubations were carried
The significance of this base change in EV-1 was ana-out on ice. Oligonucleotide complexes were separated
lyzed by gel retardation assay using short oligonucleo-on 4% nondenaturing polyacrylamide gels and visualized
tides as well as longer oligonucleotides incorporatingby autoradiography after 24 hr. The same amount of
flanking sequences (Table 1). The results of assaying theprobe was used on each lane of the gel.
long oligonucleotides are shown in Fig. 2. A control AP-For supershift experiments, complexes were formed
1 sequence (Table 1) was used to confirm that any shiftsand incubated with radiolabeled probe as described, and
observed with the MVV probes were due to AP-1 bindingthen antibody was added and the samples were further
and not an additional transcription factor in this region.incubated on ice for 30 min before electrophoresis. A
Distinct transcription factor binding patterns were ob-rabbit anti-jun antibody specific for a peptide sequence
served with the three long oligonucleotides. The long 1514from murine c-Jun and reactive against all Jun family
sequence bound both AP-1 and a second non-AP-1 factormembers was obtained from Santa Cruz Biotech, (San
(Fig. 2A, lane 6). This second protein was competed for byDiego, CA). Rabbit antisera specific for peptides derived
all three MVV-derived long sequences (lanes 7, 8, and 9),from acute myeloid leukemia proteins AML-1, -2, and -3
but by neither AP-1 (control) (lane 10) nor OCT-1 (not shown)were a kind gift from Dr. Scott Hiebert. The anti-AML-1
consensus oligonucleotides. The two long EV-1 sequencesantiserum is weakly cross-reactive with mouse and rat
did not bind AP-1 (lanes 1 and 11), even after longer autora-AML-2, while the anti-AML-2 and anti-AML-3 antisera are
diography exposure times or varying the buffer conditionscompletely specific to their cognate AML family members
and salt concentrations (data not shown). This was alsoin mouse and rat (see Meyers et al., 1996).
the case when the short oligonucleotides were used (data
not shown). The long oligonucleotides consistently showedStatistics
different affinities for the second factor, with long EV-1(7)
(lanes 11 and 15) showing higher binding than the longThe results of the transfection experiments were ana-
EV-1 oligonucleotide (lanes 1 and 5), possibly due to thelysed using Student’s two-sample T test.
G-to-A transition at position 100 (Fig. 1; Table 1). This factor
was also seen to be distinct from AP-1 due to its failure toRESULTS
interact with an anti-Jun antibody (Fig. 2B, lane 7), whereas
AP-1 binding to the EV-1 and 1514 LTRs the AP-1 factor was supershifted by the antibody (Fig. 2B,
lane 3).The LTR sequences of four MVV isolates and CAEV are
A second factor interacting with the MVV LTR is alsoaligned in Fig. 1. The LTRs of the four MVV isolates share a
a transcriptional activatorcommon organization with regard to potential transcription
factor binding sites, and the LTR from the closely related Comparison of the three LTR sequences suggested
that the site for this factor was located downstream ofCAEV shows a similar structure. However, base changes
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FIG. 1. Comparison of the LTR sequences of different MVV isolates and CAEV. Sequences are aligned against the 1514 sequence. First nucleotide
corresponds to position 8857 for 1514 (Sonigo et al., 1985), 8966 for 1772 (Andresson et al., 1993), 8998 for the EV-1 sequences (Sargan et al., 1991),
8904 for SA-OMVV (Querat et al., 1990), and 8837 for CAEV (Saltarelli et al., 1990). Potential AP-1 sites in the 1514 sequence are indicated at the top of
the figure. The consensus AP-1 sites in 1514 and 1772 are underlined in each sequence. The sequence EV-1 is that of the published EV-1 viral sequence
(Sargan et al., 1991). EV-1(7) is a representative sequence of LTR sequences observed in vivo (Sargan et al., 1995). The double-underlined sequence
represents a conserved binding site for AML (vis) in both MVV and CAEV. The MVV LTRs carry a second site for this factor adjacent to the TATA box
proximal AP-1 site. The AML (vis) consensus sequence at this site is indicated by dots above the bases. Sequences of oligonucleotides used in gel
retardation assays and the LTR sequences from which they are derived are shown beneath the LTR sequence and in Table 1.
the AP-1 site. This site possessed the consensus se- band observed that would correspond to a complex con-
taining both AP-1 and AML (vis) bound to the 1514 se-quence for the AML/PEBP2/CBF transcriptional factor
family. This second factor was therefore tentatively des- quence.
The LTRs of all the MVV isolates and CAEV contain aignated AML (vis). An oligonucleotide derived from 1514
carrying the site for AML (vis) (Fig. 1; Table 1) was tested second, upstream copy of the AML (vis) site (position 39,
Fig. 1). An oligonucleotide corresponding to the 1514in gel retardation assays (Fig. 3A). This sequence gave
a specific shift (lane 1) that was not competed by AP-1 sequence and containing this sequence (designated
USR in Fig. 1 and Table 1) was used in gel retardation(control) (lane 4) or OCT-1 (lane 5) sequences, but was
competed by the long 1514 sequence (lane 3) as well as assays. This sequence also contains a degenerate AP-
1 site and a consensus E-box (CANNTG; Fisher and God-the homologous oligonucleotide (lane 2). This AML (vis)
oligonucleotide does not contain the full AP-1 site, indi- ing, 1992). Figure 4 shows that the USR oligonucleotide
generates a single specific shift by binding AML (vis)cating that the binding site is distinct from that for AP-1.
Figure 3B demonstrates that in 1514 the binding of AP- (lane 1). The degenerate AP-1 site and E-box do not
appear to be functional as the AP-1 (control) oligonucleo-1 and this second factor is not codependent and they
may be competed independently by AP-1 (control) (lane tide does not compete (lane 6) while the USR, AML (vis),
long EV-1(7) and long 1514 oligonucleotides do (lanes4) and AML (vis) (lane 5). In no experiment was a third
TABLE 1
Synthetic Oligonucleotides Used in the Study
AP-1 (control) TTCCGGCTGACTCATCAAGCG
AAGGCCGACTGAGTAGTTCGC
AP-1 (1514) TGCTTGAGTCATAACC
ACGAACTCAGTATTGG
AP-1 (EV-1) TGCTTAAGTCATAACC
ACGAATTCAGTATTGG
Long (1514) TGATGCTTGAGTCATAACCGCA
ACTACGAACTCAGTATTGGCGT
Long (EV-1 (7)) TGATGCTTAAGTCATAACCGCA
ACTACGAATTCAGTATTGGCGT
Long (EV-1) TGATGCTAAGTCATAACCACA
ACTACGAATTCAGTATTGGTGT
AML (vis) GAGTCATAACCGCA
CTCAGTATTGGCGA
AML (consensus) GGATCCTAACCGCAAAGTCGAC
CCTAGGATTGGCGTTTCAGCTG
OCT TGTCGAATGCAAATCACTAGAA
ACAGCTTACGTTTAGTGATCTT
Upstream region (USR) TCAGGATGACACAGCAAATGTAACCGCAAGTTCTGCTT
AGTCCTACTGTGTCGTTTACATTGGCGTTCAAGACGAA
Note. Bases underlined are those which differ between the EV-1/EV-1(7) and the 1514 sequences. Sequences shown in boldface are consensus
or putative AP-1 sites. Sequence shown in boldface italics is the consensus sequence for AML-1/PEBP2/CBF (Kamaci et al., 1990; Melnikova et
al., 1993; Wang and Speck, 1992; Thornell et al., 1988).
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FIG. 2. Gel retardation and AP-1 supershift assays. (A) Comparison of the binding of ovine chondrocyte nuclear extracts to radiolabeled oligonucleo-
tide analogues of EV-1, 1514, and an ex vivo derived sequence EV-1(7). The radiolabeled probes used were as follows: long EV-1, lanes 1–5; long
1514, lanes 6–10; long EV-1(7), lanes 11–15. The competitors used were as follows: none, lanes 1, 6, and 11; long EV-1, lanes 2, 7, and 12; long
1514, lanes 3, 8, and 13; long EV-1(7), lanes 4, 9, and 14; AP-1 control, lanes 5, 10, and 15. (B) AP-1 supershift assay. The radiolabeled short AP-1
1514 and AML (vis) probes were in lanes 1–4 and 5–8, respectively. The competitors used were as follows: none, lanes 1–3 and 5–7; control AP-
1, lane 4; AML (vis), lane 8. Rabbit IgG antibodies were added to assay mixtures as follows: none, lanes 1 and 5; control IgG, lanes 2 and 6; IgG
anti-Jun antibody, lanes 3 and 7.
2–5), although the long 1514 nucleotides do not contain the upstream site confers an increased cis-activating ac-
tivity. It is unclear whether this is due to the context ofE-box sequences.
This variation in factor binding in the gel shift assay the AML (vis) site or to the presence of other degenerate
transcription factor sites in the USR sequence. The USRwas tested further in transfection experiments where
these sequences were inserted upstream of the D56 oligonucleotide also contains a copy of the degenerate
AP-1 site (position 24, Fig. 1), which is conserved be-basal promoter (Fig. 5). The data showed that the 1514
sequence was a more potent cis-activator than either tween the 1514 and the EV-1 LTRs. This sequence did
not generate a specific retarded complex in gel shiftEV-1 sequence (Fig. 5A). This result is consistent with
the observations from the gel retardation experiments assays (Fig. 4).
The relationship between the AML (vis) site in thewhere there was no detectable binding of AP-1 to the
long EV-1 sequences. The ability of the EV-1 sequences visna LTRs and the runt domain family of transcription
factors was studied further using gel shift and competi-to cis-activate a heterologous promoter suggests that
this factor is a transcriptional activator. However, neither tion assays with an oligonucleotide containing the con-
sensus AML site (Table 1; Thornell et al., 1988), and withserum nor PMA induced further activation of the D56
basal promoter over and above that of the vector without antisera directed against peptides in each of the known
AML family members. In these assays, extracts frominsert (data not shown), possibly due to the chondrocytes
being maximally activated already in vitro. ovine alveolar chondrocytes (Fig. 6), macrophages (Fig.
7), and spleen (Fig. 8) were used. In these experiments,In order to determine if AML (vis) is a transcriptional
activator, multimerized sites were placed upstream of the shift patterns seen differed in detail for each extract,
but were the same whether AML (vis) or the AML (con-the c-fos basal promoter in the vector D56. The results
showed that the factor does function as a trans-activator sensus) site was used. However, in each case a higher
proportion of the oligonucleotide was shifted when theof transcription following incubation with 5% FCS or PMA
(Fig. 5B). Again the factor appeared to be maximally in- AML (consensus) site was used than when the AML (vis)
site was used. When cold competitor oligonucleotidesduced in chondrocytes in in vitro culture in the absence
of serum or PMA (data not shown). were added to the binding reactions, the AML (consen-
sus) and the AML (vis) both reduced binding to eachThe USR sequence is also capable of cis-activating
the D56 heterologous promoter as shown in Fig. 5C. other.
In chondrocytes, the AML (consensus) oligonucleotideComparison of other single copies of sequences con-
taining the AML (vis) site suggests that the context of gave an additional major shift (Fig. 6, lane 1, bottom
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FIG. 3. Comparison of the AML (vis) with long 1514 and long EV-1 sequences (Table 1) in gel retardation assays. The assays were performed
with radiolabeled oligonucleotide probes and ovine chondrocyte nuclear extracts. (A) The radiolabeled AML (vis) probe was used in lanes 1–5.
The competitors used were as follows: none, lane 1; AML (vis), lane 2; long 1514, lane 3; AP-1 control, lane 4; OCT-1, lane 5. (B) The radiolabeled
long 1514 probe was used in lanes 1–5. The competitors used were as follows: none, lane 1; long 1514, lane 2; long EV-1(7), lane 3; AP-1 control,
lane 4; AML (vis), lane 5; OCT-1, lane 6.
arrow) with chondrocyte extracts. The major shifts ob- sites were used. Supershifts were seen with antibodies
directed against AML-1 (Fig. 7A, lane 2 versus lane 1) orserved were inhibitable by excess cold AML (vis) (Fig. 6,
lane 2) or AML (consensus) oligonucleotide (Fig. 6, lane AML-2 (Fig. 7A, lane 3 versus lane 1). The latter antiserum
qualitatively supershifted the top shift band in this extract3). In the converse experiment, gel shifts were obtained
with labeled AML (vis) oligonucleotide (Fig. 6, lanes 4 – without affecting the bottom band. No supershifting was
seen with the anti-AML-3 antiserum (Fig. 7A, lane 4).6). The major shift (Fig. 6, lane 4, arrow) was inhibitable
with unlabeled AML (vis) (Fig. 6; lane 5) or AML (consen- Similar results were obtained with the labeled AML (con-
sensus) oligonucleotide (Fig. 7B, lanes 2 and 3, respec-sus) oligonucleotide (Fig. 6, lane 6), though the AML (con-
sensus) oligonucleotide gave better inhibition than the tively), though the shifted bands were more prominent.
A faint supershift was obtained with the anti-AML-3 anti-AML (vis) oligonucleotide.
In macrophages (Fig. 7), the AML (consensus) was serum (Fig. 7B, lane 4). The anti-AML-2 shifted band was
inhibited by a 100-fold excess of cold AML (consensus)able to abolish detectable binding to the labeled AML
(vis) when present in a 100-fold excess (Fig. 7A, lane 9 oligonucleotide (Fig. 7B, lane 5 versus lane 3).
The single major shift seen with labeled AML (vis) inversus lane 1), while in binding to labeled AML (consen-
sus), a 2000-fold excess of AML (vis) (Fig. 7B, lane 8 chondrocytes (Fig. 6, lane 1) was supershifted weakly by
the anti-AML-1 antiserum, but not supershifted at all withversus lane 1) or a 100-fold excess of AML (consensus)
(Fig. 7B, lane 9 versus lane 1) competed similarly, but the anti-AML-2 or anti-AML-3 antisera (data not shown).
A similar result was obtained when labeled AML (con-not completely. A 2000-fold excess of AML (consensus)
did, however, abolish binding (data not shown). In all sensus) oligonucleotides were used, though the anti-
AML-1 supershift was more marked than when labeledreactions, poly(dI–dC) was present in 10,000-fold ex-
cess. AML (vis) was used (data not shown). Spleen gave a
much broader shift band of complex structure. In thisAnti-AML antisera were able to cause supershifts with
macrophage extracts, and once again the results were extract, anti-AML-1 gave two weak supershift complexes
with labeled AML (vis) (Fig. 8, lane 2) while anti-AML-2similar whether the AML (consensus) or the AML (vis)
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factor was tentatively designated AML (vis). Unlike AP-
1, the binding sites for AML (vis) are conserved between
all MVV isolates sequenced to date (Sonigo et al., 1985;
Saltarelli et al., 1990; Querat et al., 1990; Sargan et al.,
1991; Andresson et al., 1993), suggesting that this tran-
scription factor plays a key role in the regulation of MVV
replication. In contrast, the presence of a consensus AP-
1 site appears to be restricted to the 1514 virus and its
derivatives (Sonigo et al., 1985; Andresson et al., 1993).
Both the 1514 and the 1772 LTRs carry a consensus AP-
1 site. In contrast, no consensus site is found in either
the EV-1 or the SA-OMVV LTRs (Fig. 1).
In the 1514 LTR, the TATA box proximal AP-1 site has
been described as a key regulator of transcription (Ga-
buzda et al., 1989; Hess et al., 1989). It has been reported
to be important for both inducible and tat activated tran-
scription from the 1514 LTR. The failure to observe inter-
action of AP-1 with the EV-1 LTR sequence does not
directly rule out the possibility that the degenerate AP-1
site at this position has an affinity too low to allow binding
to be detected in the gel retardation assay. Degenerate
AP-1 sites that do not bind in vitro, but that are active in
the context of a basal promoter, have been described
(Jain et al., 1992). However, when this region from the
1514 site and that from the EV-1 site are compared with
regard to their ability to drive transcription, it is clear that
FIG. 4. Gel retardation analysis of the 1514 USR sequence. Autora- the sequence variation results in an altered cis regulatory
diograph of a gel retardation assay using chondrocyte extracts and
function. The difference in activity argues stronglyradiolabeled USR oligonucleotide as probe (see Fig. 1). The competitors
against an interaction of AP-1 with this site in this cellused were as follows: none, lane 1; USR, lane 2; AML (vis), lane 3;
long EV-1(7), lane 4; long 1514, lane 5; AP-1 control, lane 6; OCT-1, system. Rather, the cis regulatory activity of this region
lane 7. may be fully accounted for by the AML (vis) site.
A second, upstream copy of the AML (vis) site also lies
in close proximity to a degenerate AP-1 site in both 1514
gave a single strong supershift (Fig. 8, lane 3). Anti-AML-
and EV-1. A single oligonucleotide copy was found to be
3 did not produce any supershifts (Fig. 8, lane 4). The
as active as the promoter proximal AP-1/AML (vis) element
supershift obtained with anti-AML-2 was inhibited com-
of virus 1514. No AP-1-specific shift was found in gel retar-
pletely with a 100-fold excess of cold AML (consensus)
dation assays, suggesting that the functional activity was
oligonucleotide (Fig. 8, lanes 5 and 6). The anti-AML-1
due to the AML (vis) site. However, as for the promoter
antiserum gave two distinct supershifted bands with the
proximal site, a role for the degenerate AP-1 site in vivo
labeled AML (consensus) oligonucleotide (Fig. 8, lane 7),
cannot be totally excluded (Jain et al., 1992). The relation
while both anti-AML-2 and anti-AML-3 antisera produced
to consensus is also not predictive of AP-1 binding (Ryseck
strong single supershifts (Fig. 8, lanes 8 and 9, respec-
and Bravo, 1991) as both the sequences in the core ‘‘con-
tively).
sensus’’ site and the flanking sequences may determine
site affinity. In addition, the composition of the AP-1 complex
DISCUSSION
affects the affinity of binding to a given sequence (Ryseck
and Bravo, 1991). This raises the question as to whetherIn the present study, some of the effects of LTR se-
quence variation between different MVV isolates on tran- or not the degenerate AP-1 site within the EV-1 LTR discrim-
inates between AP-1 complexes of different compositions.scriptional factor binding are assessed. Differences were
observed in the transcription factors interacting with the This could be tested by using in vitro translated proteins
to determine if certain combinations of Jun and Fos/FraLTRs of the 1514 and EV-1 viruses. No direct evidence
was found of AP-1 interaction with the EV-1 LTR. This proteins are able to interact preferentially with the 1514
and EV-1 LTRs.may, in part, explain our previous observation that EV-1
LTR variants show lower transcriptional activity than the One interesting area of speculation is the effect of
altering the position of the consensus AP-1 site in the1514 LTR (Sargan et al., 1995). In contrast, a second
factor was seen to bind both 1514 and EV-1 LTRs. The 1772 virus compared to 1514. The movement of sites
within the promoter region may alter the topology of thebinding site possessed the consensus sequence for the
AML/PEBP2/CBF family of transcription factors, and the DNA/protein complex formed and such alterations can
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FIG. 5. (A) Transfection of long 1514, long EV-1(7), and long EV-1 sequences inserted in the D56 c-fos basal promoter vector into chondrocytes. The
results are expressed as the fold increase in CAT expression over the D56 vector without any insert, and they are the mean / SD of 4 (1514; EV-1) or
5 (EV-1(7)) independent transfections. (B) Transfection of AML (vis) sequence inserted in the D56 c-fos basal promoter vector into chondrocytes which
were subsequently incubated with either 5% FCS or PMA (100 ng/ml). The results are expressed as the fold increase in CAT expression over the D56
vector without any insert, and are the mean / SD of 5 (FCS) or 4 (PMA) independent transfections. (C) Transfection of the USR sequence in the D56 c-
fos basal promoter vector into chondrocytes which were subsequently incubated with 5% FCS. The results are expressed as the fold increase in CAT
expression over the D56 vector without any insert, and are the mean / SD of eight USR or four long EV-1(7) independent transfections.
have a considerable impact on promoter function and The conservation of the consensus AP-1 sites in 1514-
like viruses compared to EV-1 and SA-OMVV raises ques-activity (Giese et al., 1995; Cohen et al., 1994; Tjuan and
Maniatis, 1994; Du et al., 1993; Natesan and Gilman, tions as to whether these two sets of viruses have fine-
tuned their transcriptional regulation. Previous compari-1993; Thanos and Maniatis, 1992).
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tained such a site. In contrast, all EV-1 ex vivo LTRs
(Sargan et al., 1991, 1995) contained putative AML (vis)
binding sites with 39/54 containing the high-affinity con-
sensus site. It is important to note that the upstream AML
(vis) site is in a region highly conserved between all MVV
isolates and CAEV. The conservation of sites for this
factor suggests that it may play an important role in con-
trolling transcription in these two viruses. It is interesting
to speculate that differences in usage of AP-1 or AML
(vis) between 1514 and EV-1 may play a role in determin-
ing whether the CNS or the pulmonary system becomes
clinically affected.
Transcription factors that bind AML (consensus) sites
have been described under a variety of names in several
systems. First identified as SL3-3 virus enhancer factor
1 (SEF-1; Thornell et al., 1988), this factor has also been
called polyoma enhancer-binding protein 2 (PEBP2; Ka-
maci et al., 1990), AKV core-binding factor (CBF; Boral et
FIG. 6. Autoradiograph showing gel retardation assays using radiola- al., 1989), or acute myeloid leukemia 1 gene product
beled AML (consensus) or radiolabeled AML (vis) and nuclear extracts
(AML1; Miyoshi et al., 1991). The site is also found in thefrom chondrocytes. AML (consensus) (lanes 1–3); AML (vis) (lanes 4–
enhancers of many genes abundantly expressed in cells6). The competitors used in 500-fold excess were as follows: none
(lanes 1 and 4); AML (vis) (lanes 2 and 5); AML (consensus) (lanes 3 of the myeloid lineages including T cell receptor g, d,
and 6). and b; CD-3 e and d; immunoglobulin m; the colony-stimu-
lating factors MCSF and GMCSF; a number of interleu-
kins, and TNFa and TNFb. Site-directed mutation studiesson of the transcriptional activity of EV-1 LTR variants to
have shown that the site is essential for function of at1514 indicated that these different LTR structures do give
least the first two of these genes (Hsiang et al., 1993;rise to different promoter activities (Sargan et al., 1995).
Redondo et al., 1991). Multiple polypeptides have beenWhether this alteration in transcriptional regulation has
shown to bind this site, but the characterized transcrip-any effect on the course of viral infection in vivo is un-
tion factors are heterodimers in which ubiquitously ex-known. However, it is clear that these differences in the
pressed b subunits, which are products of a single geneLTR structure between the 1514 and EV-1 viruses persist
although subject to alternative splicing (Wang et al.,during infection in vivo.
1993), bind one of at least three tissue-specific and DNAThe sequence EV-1(7) corresponds to that prevalent
binding a subunits with homology to the Drosophila runtin vivo in blood or lymph of EV-1 infected animals (Sargan
gene (Wang and Speck, 1992; Bae et al., 1994; Ogawaet al., 1995). This previous study indicated that the pres-
et al., 1993; Levanon et al., 1994). Further heterogeneityence of a consensus AP-1 site within the LTR was not a
is also generated in the a subunits by alternate splicingrequirement for viral persistence in vivo. None of the LTR
sequences obtained from EV-1 infected animals con- (Levanon et al., 1996). Interactions of different members
FIG. 7. Gel retardation assay of interactions between AML oligonucleotides and alveolar macrophage nuclear extract. (A) Autoradiography of a
gel retardation assay using radiolabeled AML (vis) oligonucleotide (lanes 1–9) or AML (consensus) oligonucleotide (lane 10) as probe. Rabbit
polyclonal antisera and unlabeled competitor oligonucleotides were added as follows: none, lane 1; anti-AML-1, lane 2; anti-AML-2, lane 3; anti-
AML -3, lane 4; anti-AML-2 / AML (consensus) (1100 excess), lane 5; AML (consensus) (11 excess), lane 6; AML (consensus) (110 excess), lane
7; AML (consensus) (1100 excess), lane 8; AML (vis) (12000 excess), lane 9; anti-AML-2, lane 10. (B) Autoradiography of a gel retardation assay
using radiolabeled AML (consensus) oligonucleotide (lanes 1–10) as probe with macrophage extract (lanes 1–9) or no extract (lane 10). Rabbit
polyclonal antisera and unlabeled competitor oligonucleotides were added as follows: none, lane 1; anti-AML-1, lane 2; anti-AML-2, lane 3; anti-
AML -3, lane 4; anti-AML-2 / AML (consensus) (1100 excess), lane 5; AML (vis) (120 excess), lane 6; AML (vis) (1200 excess), lane 7; AML (vis)
(12000 excess), lane 8; AML (consensus) (1100 excess), lane 9; anti-AML-2, lane 10.
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